Skip header and navigation

2 records – page 1 of 1.

Incidence of biopsy-proven glomerulonephritis.

https://arctichealth.org/en/permalink/ahliterature161719
Source
Nephrol Dial Transplant. 2008 Jan;23(1):193-200
Publication Type
Article
Date
Jan-2008
Author
Ole Wirta
Jukka Mustonen
Heikki Helin
Amos Pasternack
Author Affiliation
Department of Medicine, Tampere University Hospital, Finland. ole.wirta@pshp.fi
Source
Nephrol Dial Transplant. 2008 Jan;23(1):193-200
Date
Jan-2008
Language
English
Publication Type
Article
Keywords
Adult
Biopsy
Europe - epidemiology
Female
Finland - epidemiology
Glomerulonephritis - epidemiology - pathology
Humans
Incidence
Male
Middle Aged
Abstract
The reported biopsy-proven glomerulonephritis incidence varies according to population characteristics, the unknown true glomerulonephritis incidence and biopsy rate. Reported glomerulonephritis incidence should be evaluated against the biopsy rate.
We report here the glomerulonephritis incidence in our University Hospital (UH) consecutive biopsy material. It is compared to those from surrounding central hospitals (CH), previous single-centre studies and European biopsy registries (EBR). Biopsy rate, when reported, has been considered.
The annual biopsy rate/10(5), median (min-max), at the UHs was 25.4 (15.6-35.1). At the CHs it was 8.7 (5.1-12.6). In previous single-centre studies it has been 18.7-21.5. In the EBRs it has been between 1.0 and 6.9 when reported. The annual incidences (median, min-max) per 10(5) (1980-2000) at the UH were as follows: proliferative glomerulonephritis (9.5, 6.8-18.1), non-proliferative glomerulonephritis (6.7, 3.4-12.6), the four major glomerulonephritis groups MesGN (7.7, 4.4-15.9), ECGN/FPGN-complex (1.4, 0.5-3.2), MCGP/FSGS-complex (0.9, 0.2-2.7) and MGN (1.4, 0.5-2.4) these which findings were compatible with the single-centre studies and higher than those of the CHs and in the EBRs. Biopsy rate had a major impact on the annual glomerulonephritis incidences explaining 60% of the variation. The relative frequency of MesGN was the highest by all observers, followed by the ECGN/FPGN-complex, MGN and MCGP/FSGS-complex whose frequencies did not differ much. For every patient commencing renal replacement therapy (Finnish Renal Replacement Registry Data) due to glomerulonephritis there were about 11 subjects with biopsy-proven glomerulonephritis, a relationship compatible with previous reports.
The incidence of any glomerulonephritis of 17.6 per 10(5) population was comparable to those from the single-centre studies, but higher than in European biopsy registries, a fact largely explained by biopsy rates.
PubMed ID
17720989 View in PubMed
Less detail
Source
Duodecim. 2006;122(2):208-14
Publication Type
Article
Date
2006